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ABSTRACT
Type V CRISPR–Cas12a systems provide an alter-
nate nuclease platform to Cas9, with potential ad-
vantages for specific genome editing applications.
Here we describe improvements to the Cas12a sys-
tem that facilitate efficient targeted mutagenesis in
mammalian cells and zebrafish embryos. We show
that engineered variants of Cas12a with two different
nuclear localization sequences (NLS) on the C ter-
minus provide increased editing efficiency in mam-
malian cells. Additionally, we find that pre-crRNAs
comprising a full-length direct repeat (full-DR-crRNA)
sequence with specific stem-loop G-C base substitu-
tions exhibit increased editing efficiencies compared
with the standard mature crRNA framework. Finally,
we demonstrate in zebrafish embryos that the im-
proved LbCas12a and FnoCas12a nucleases in com-
bination with these modified crRNAs display high
mutagenesis efficiencies and low toxicity when de-
livered as ribonucleoprotein complexes at high con-
centration. Together, these results define a set of en-
hanced Cas12a components with broad utility in ver-
tebrate systems.
INTRODUCTION
The breadth of Class 2 CRISPR–Cas single effector nucle-
ases that have been identified and characterized continues
to expand (1–4). Many of these newly discovered Class 2
systems have novel properties that differ from the ubiqui-
tously employed Type II Cas9 system, making them partic-
ularly amenable to specific biological and therapeutic appli-
cations (5–7). In particular, the Type VCas12a (Cpf1) DNA
endonucleases have several unique attributes for genome
editing applications (Figure 1A) (1). First, characterized
Cas12a nucleases typically recognize a T-rich Protospacer
adjacent motif (PAM) element at the 5′ side of the proto-
spacer, which facilitates targeting AT-rich genomic regions
that can be challenging to target with Cas9-based nucle-
ases (1,8,9). Second, unlike Cas9 nucleases, Cas12a nucle-
ases are programmed with a single crRNA that does not in-
clude a tracrRNA (1). Thus, the shorter crRNA of Cas12a
(∼42 nt) compared with the sgRNA of Cas9 (∼100 nt)
is more amenable to the synthesis of chemically-modified
guide RNAs that improve nuclease activity within mam-
malian cells (10,11). Third, Cas12a produces double-strand
breaks with 5′ overhangs that are distal from its PAM ele-
ment (1,8), which are distinct from the blunt ends produced
by SpCas9. The distal cleavage within the spacer region po-
tentially permits Cas12a to continue cutting even after ini-
tial sequence alterations have occurred via imprecise DNA
repair; this behavior is distinct from Cas9, where primary
lesions usually prevent subsequent targeting. Consequently,
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Figure 1. Position and number of NLS improves genome editing byAsCas12a, LbCas12a and FnoCas12a. (A) General schematic of Cas12a (B). Schematic
representation of a series of Cas12a constructs with different nuclear localization signals. Lesion rates determined by deep sequencing for SpCas9, As-
Cas12a, LbCas12a and FnoCas12a with different combinations of NLSs at the DNMT1 (C) and EMX1 (D) target sites, respectively. Boxed sequences
represent SpCas9 targeting sites, red color labeledNGGPAM.Underlined sequences represent Cas12a targeting sites, blue color labeled TTTV PAM.Data
are from three independent biological replicates performed on different days with expression constructs delivered by transient transfection in HEK293T
cells (Supplementary Table S1). Error bars indicate ±s.e.m. Statistical significance is determined by two-tailed Student’s t-test: ‘***’ denotes P < 0.001,
‘**’ denotes P < 0.01, respectively (Supplementary Table S7).
Cas12a mutagenesis products are biased toward larger dele-
tions than are typically produced by Cas9 (1,12). This mu-
tagenesis behavior should increase the efficiency with which
genomic features, such as transcriptional and splicing regu-
latory elements (13–15), can be selectively removed from the
genome. Fourth, Cas12a proteins contain an active site for
processing precursor crRNAs (pre-crRNA) arrays, which
can be harnessed for multiplex genome editing from a sin-
gle transcript (8,16–18). Finally, Cas12a displays higher
genome editing precision than SpCas9 based on multiple
unbiased genome-wide analyses (12,16,17). Thus, Cas12a
nucleases could provide a valuable alternative to Cas9 for
many genome editing applications.
Like Cas9, Cas12a has been employed for targeted mu-
tagenesis in fruit flies (18), mammalian cells (1,9,12,16),
mouse embryos (19–21), zebrafish (22) and a variety of
plant systems (26–28). Furthermore, Cas12a has been used
successfully to restore dystrophin function via targeted gene
correction in embryos of a mouse model of Duchenne mus-
cular dystrophy (DMD) or by exon skipping via the genera-
tion of segmental deletions in anDMD-iPSC line (7). Addi-
tionally, Cas12a has been adapted to facilitate targeted cy-
tosine base editing within the genome (23). Together, these
results demonstrate that Cas12a-based systems have the po-
tential to facilitate a broad variety of genome editing goals
with both research and therapeutic applications.
Most studies have employed LbCas12a or AsCas12a in
vertebrate systems because of their promising activity in cell
culture assays in initial reports (1,12). LbCas12a and As-
Cas12a prefer a TTTV PAM element (1,9), and the range
of targetable sequences has been extended through modifi-
cations to residues involved in their PAM recognition (24).
Notably, FnoCas12a prefers a more compact TTN PAM
element (1,25,26), which provides an expanded targeting
range relative to either LbCas12a or AsCas12a. Recently,
FnoCas12a has been shown to be effective in mammalian
systems (26) and plants (27). In many instances, the muta-
genesis activity of Cas12a nucleases is modestly lower than
observed for SpCas9 (12,19). Therefore, improvements in
the cleavage activity of Cas12a-based nucleases could ex-
pand its utility in a variety of eukaryotic systems.
We have focused on improving the editing efficiency of
Cas12a for targeted mutagenesis in mammalian cells and
zebrafish embryos through alteration of its protein and
crRNA components. The mutagenesis efficiency of As-
Cas12a, LbCas12a and FnoCas12a in mammalian systems
was improved through the incorporation of an additional
nuclear localization signal (NLS) sequence within the pro-
tein. The editing efficiency of Cas12a in mammalian cells
and zebrafish embryos was further increased through ex-
tension of the 5′ end of the crRNA and by altering the
base composition of the hairpin within the pseudoknot.
Together, these enhancements will increase the utility of
Cas12a nucleases in a variety of systems for genome edit-
ing applications.
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MATERIALS AND METHODS
Zebrafish husbandry
The use of Zebrafish was in accordance with established
protocols (28) and in conformity with Institutional Animal
Care and Use Committee guidelines of the University of
Massachusetts Medical School. All Cas12a nuclease pro-
tein and crRNA injections were performed in the wild type
Ekkwill 2 (EK2) zebrafish line.
Plasmid constructs
Cas12a nuclease experiments for transient transfection in
cell culture employed the following plasmids: All Cas12a
crRNAs are expressed via a U6 promoter from a pBlue-
script2 SK+ vector (Agilent). AsCas12a, LbCas12a and
FnoCas12a were cloned from Addgene vectors (#69982,
#69988 and #69976) that were a generous gift of the Zhang
laboratory (1). All new Cas12a constructs were expressed
via a CMV IE94 promoter from a pCS2-Dest gateway plas-
mid (29). The SpCas9 plasmid expression construct for
transient transfections has been previously described (29).
A corresponding pBluescript U6 SpCas9 sgRNA expres-
sion vector was constructed for these assays. All Cas12a
and SpCas9 protein expression for protein purification
utilized pET-21a protein expression plasmids (Novagen).
LbCas12a-2xNLS and FnoCas12a-2xNLS expression con-
structs were constructed containing a 6xHis tag at the C-
terminus for affinity purification. Our pET-21a 3xNLS-
SpCas9 protein expression plasmid has been previously de-
scribed (Wu et al.Nature Medicine in press).Representative
protein sequences for the Cas12a constructs (both plasmid
expression and protein expression constructs) and cloning
vectors for the U6 expression vectors for the crRNA ex-
pression cassettes are shown in Supplementary SFigure 23.
These plasmids have been deposited with Addgene for dis-
tribution to the community.
Cell culture nuclease assays
Human Embryonic Kidney (HEK293T) and HeLa cells
were cultured in high glucose DMEM with 10% FBS
and 1% Penicillin/Streptomycin (Gibco) in a 37◦C in-
cubator with 5% CO2. K562 and Jurkat cells were cul-
tured in RPMI 1640 medium with 10% FBS and 1%
Penicillin/Streptomycin (Gibco) in a 37◦C incubator with
5% CO2. These cells were authenticated by University of
Arizona Genetics Core and tested for mycoplasma contam-
ination at regular intervals. For transient transfection, we
used early to mid-passage cells (passage number: 5–25). Ap-
proximately 1.6 × 105 cells are transfected using Polyfect
transfection reagent (Qiagen) in 24-well format according
to the manufacturer’s suggested protocol. Following plas-
mid amounts were used for transient transfections for sin-
gle target sites: 50 ng of Cas12a nuclease expression vector,
50ng crRNA expression vector and 100 ng mCherry plas-
mid. Cas12a RNPs were delivered to HEK293T, Jurkat or
K562 cells by nucleofection. LbCas12a or FnoCas12a pro-
tein were complexed with the desired crRNA generated by
in vitro transcription (described below) at a ratio of 1:2.5
(16 pmol protein complexed to 40 pmol crRNA) in Neon
R buffer (Thermo Fisher Scientific) and incubated at RT
for 15–20 min. For HEK293T cells, the Cas12a RNP com-
plex was then mixed with 1 × 105 cells in Neon R buffer at
the desired concentration and electroporated using Neon®
Transfection System 10 LKit (ThermoFisher Scientific) us-
ing the suggested electroporation parameters: Pulse voltage
(1500 V), Pulse width (20 ms), Pulse number (2). For Jurkat
and K562 cells, the Cas12a RNP complex was then mixed
with 2× 105 cells in NeonR buffer at the desired concentra-
tion and electroporated using Neon® Transfection System
10 l Kit (Thermo Fisher Scientific) using the suggested elec-
troporation parameters: Pulse voltage (1600 V), Pulse width
(10 ms), Pulse number (3).
AsCas12a immunohistochemistry
HEK293T cells are transfected in 6-well format via Poly-
fect transfection reagent (Qiagen) using the manufacturer’s
suggested protocol with 300 ng of each AsCas12a plasmid
(or SpCas9–2xNLS) and 150 ng of crRNA (or sgRNA)
expression plasmid on a cover slip. Forty eight hours fol-
lowing transfection, transfection media was removed, cells
were washed with 1x PBS and fixed with 4% formalde-
hyde in 1xPBS for 15 min at room temperature. Follow-
ing blocking (blocking solution: 2% BSA, 0.3% Triton X-
100 within 1× PBS), samples were stained with mouse anti-
hemagglutinin (Sigma, H9658, 1:500), and Alexa 488 don-
key anti-mouse IgG (H+L; Invitrogen, A-21202, 1:2000),
sequentially. VECTASHIELD Mounting Medium with
DAPI (Vector Laboratories, H-1200) was used to stain the
nuclei and tomount the samples on slide. Images were taken
with Zeiss AxioPlan 2 IE Motorized Microscope System.
LbCas12a and FnoCas12a protein purification
Protein purification for LbCas12a-2xNLS or FnoCas12a-
2xNLS used a common protocol. The plasmid expressing
LbCas12a-2xNLS (or FnoCas12a-2xNLS) was introduced
into Escherichia coli Rosetta (DE3) pLysS cells (EMDMil-
lipore) for protein overexpression. Cells were grown at 37◦C
to an OD600 of ∼0.2, then shifted to 18◦C and induced for
16 h with IPTG (1 mM final concentration). Following in-
duction, cells were pelleted by centrifugation and then re-
suspended with Nickel-NTA buffer (20 mM TRIS + 1 M
NaCl + 20 mM imidazole + 1 mM TCEP, pH 7.5) supple-
mented with HALT Protease Inhibitor Cocktail, EDTA-
Free (100X) [ThermoFisher] and frozen on dry ice. Cells
were then thawed, an additional aliquot of HALT Protease
Inhibitor Cocktail added followed by cell lysis with M-110s
Microfluidizer (Microfluidics) following the manufacturer’s
instructions. The protein was purified with Ni-NTA resin
and eluted with elution buffer (20 mM Tris, 500 mMNaCl,
250 mM Imidazole, 10% glycerol, pH 7.5). Cas12a protein
was dialyzed overnight at 4◦C in 20 mM HEPES, 500 mM
NaCl, 1 mM EDTA, 10% glycerol, pH 7.5. Subsequently,
Cas12a protein was step dialyzed from 500mMNaCl to 200
mM NaCl (final dialysis buffer: 20 mM HEPES, 200 mM
NaCl, 1 mM EDTA, 10% glycerol, pH 7.5). Next, the pro-
tein was purified by cation exchange chromatography (col-
umn = 5ml HiTrap-S, Buffer A = 20 mM HEPES pH 7.5
+ 1 mM TCEP, Buffer B = 20 mM HEPES pH 7.5 + 1 M
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NaCl + 1 mM TCEP, Flow rate = 5 ml/min, CV = column
volume = 5 ml) followed by size-exclusion chromatogra-
phy (SEC) on Superdex-200 (16/60) column (Isocratic size-
exclusion running buffer= 20mMHEPES pH 7.5, 300mM
NaCl, 1 mM TCEP). The primary protein peak from the
SEC was concentrated in an Ultra-15 Centrifugal Filters
Ultracel -30K (Amicon) to a concentration of between 30
and 50 M. The purified protein quality was assessed by
SDS-PAGE/Coomassie staining to be >95% pure.
Initial studies with FnoCas12a–2xNLS protein in ze-
brafish were produced from a FnoCas12a-2C-NLS-TEV-
MBP-6xHis expression construct, where MBP was cleaved
following the Hexa-His purification. TEV cleavage of MBP
incorporated two extra steps: 1. Determine total protein
concentration following Hexa-His purification (described
above) by measuring absorbance at 280 nm blanked against
elution buffer. Add 1:10 (w/w) of TEV protease. 2. Dialyze
FnoCas12a-MBP eluate + TEV protease overnight against
20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP, and
10% glycerol. The final cleaved FnoCas12a product was pu-
rified by cation exchange chromatography (Column = 5 ml
HiTrap-S, Buffer A = 20 mM HEPES pH 7.5 + 1 mM
TCEP, Buffer B = 20 mM HEPES pH 7.5 + 1 M NaCl +
1 mM TCEP, Flow rate = 5 ml/min, CV = column volume
= 5 ml) followed by size-exclusion chromatography (SEC)
on Superdex-200 (16/60) column (Isocratic size-exclusion
running buffer = 20 mM HEPES pH 7.5, 300 mM NaCl,
1 mM TCEP). The primary protein peak from the SEC
was concentrated in an Ultra-15 Centrifugal Filters Ultra-
cel -30K (Amicon) to a concentration of between 30 and
50 M. The purified protein quality was assessed by SDS-
PAGE/Coomassie staining to be >95% pure.
In vitro transcription of crRNAs
For crRNA generation, DNA templates for crRNA tran-
scription were PCR assembled by annealing and extend-
ing a common scaffold oligonucleotide and a target se-
quence specific oligonucleotide (Invitrogen), which contains
sequence complementary to the common scaffold oligonu-
cleotide on the 3′ end (Supplementary Table S8). To gener-
ate each crRNA expression template, a 60 l PCR contain-
ing 1X Phusion Buffer, 200 M common scaffold oligonu-
cleotide and target sequence specific oligonucleotide, and
1.2 U of Phusion DNA polymerase (NEB Cat#M0530L)
was performed using the following thermocycling program:
initial incubation 98◦C for 15 s, 40 cycles of 98◦C for 10 s,
60◦C for 15 s, 72◦C for 5 s, final extension at 72◦C for 1 min,
and hold at 4◦C. Production of each double stranded cr-
RNA DNA template was validated by 3% TBE agarose gel
with ethidium bromide, and then crRNA DNA templates
were purified by ethanol precipitation using 3M sodium ac-
etate and 2 g glycogen as a carrier.
For crRNA generation, IVT was performed using the
MEGAscript® T7 Kit (Ambion Cat#AM1334). Half re-
actions (10 l) using 800 ng of crRNADNA template were
incubated for a minimum of 5 h at 37◦C. To eliminate the
DNA template following crRNA production by IVT, reac-
tions were treatedwithDNase TURBO (ThermoFisher) for
40 min at 37◦C. Production of each crRNA was validated
by 3% TBE agarose gel with ethidium bromide. Following
validation, crRNAs were purified by ethanol precipitation
with 3M sodium acetate and resuspended in 30 l of nucle-
ase free water. Finally, crRNA quality was again validated
by 3% TBE agarose gel and quantified by A260.
Injection of zebrafish embryos with RNP
We performed microinjection of Cas12a protein and cr-
RNAs into one-cell-stage zebrafish embryos according to
standard methods (30). Briefly, in order to assemble RNPs,
LbCas12a, or FnoCas12a protein was complexed with the
corresponding crRNA at 2.5-fold excess (Supplementary
Table S8) in nuclease free water with 1:10 phenol red and
incubated for 20 minutes at room temperature. Injection so-
lutions were held on ice until utilization. Injections of 1 and
2 nl RNP solution were performed into the blastomere of
∼60 one-cell-stage zebrafish embryos. Heat shock treated
embryos were incubated at 34◦C for 4 h immediately fol-
lowing injection and then shifted to 28.5◦C (22). Embryos
without heat shock were incubated at 28.5◦C. All experi-
ments were performed in biological triplicate by three indi-
viduals.
At 24 hpf, the morphology of injected embryos was as-
sessed. The embryos were assigned to three morphology
classes: normal, abnormal and dead (Supplementary Table
S6). The distributions of these morphological classes were
used to assess the statistical significance of the impact of dif-
ferent crRNA frameworks or different Cas12a RNP doses
on zebrafish development. R, a system for statistical com-
putation and graphics, was used for this analysis (31). Nu-
clease toxicity, measured as proportion of abnormal and
dead animals, was first arcsin transformed to homogenize
the variance. Levene’s test indicates that the assumption of
homogeneity of variances was met for both Heatshock+
and Heatshock– experiments. Three-way analysis of vari-
ance (ANOVA) with Completely Randomized Design was
performed to test whether there are main effects of RNP
dose, target sites and crRNA framework, and whether there
is a significant dose-dependent guide frameworks impact
(Supplementary Table S7).
Preparation of zebrafish genomic DNA for analysis of editing
efficiency
For analysis of RNP activity and resulting insertions and
deletions for each nuclease treatment group (or uninjected
controls), pooled genomic DNA samples (n= 20) were har-
vested at 24 hpf from embryos displaying normal develop-
mental morphology using the DNeasy Blood & Tissue kit
(QIAGEN Cat#69506).
For initial analysis, pooled genomic samples were PCR
amplified for Sanger sequencing (Supplementary Table S8).
For each genomic DNA sample, a 25l reaction containing
1X Phire Buffer, 100 M forward and reverse primer, and
0.5l of PhireHot Start IIDNAPolymerase (Thermofisher
Cat#F122L) was performed using the following thermocy-
cling program: initial denaturation 98◦C for 3 minutes, 31
cycles of 98◦C for 20 s, 62◦C 20 s, 72◦C for 30 s, final ex-
tension at 72◦C for 5 min, and hold at 12◦C. DNA ampli-
con production was validated by 3% TAE agarose gel with
ethidium bromide. DNA amplicons were purified by Zymo
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DNA clean and concentrator 5 column (Zymo D4014).
Sanger sequencing was performed by a commercial service
(Genewiz) and chromatograms were analyzed for indel rate
and composition using TIDE Analysis (32) or Synthego
ICE (https://ice.synthego.com/#/).
Target site indel frequency analysis in mammalian cells or
zebrafish embryos by deep sequencing
Library construction for deep sequencing is modified from
our previous report (29). For analysis of mammalian cell
culture experiments, cells were harvested 72 h after trans-
fection (or nucleofection) and genomic DNA extracted
with GenElute Mammalian Genomic DNA Miniprep Kit
(Sigma). For analysis of zebrafish embryos the genomic
DNA preparation is described above. Briefly, regions flank-
ing each target site were PCR amplified using locus-specific
primers (Supplementary Table S8) bearing tails comple-
mentary to the Truseq adapters as described previously (29).
25–50 ng input genomic DNA is PCR amplified with Phu-
sion High Fidelity DNA Polymerase (New England Bio-
labs): (98◦C, 15 s; 67◦C 25 s; 72◦C 18 s) × 30 cycles. 1 l
of each PCR reaction was amplified with barcoded primers
to reconstitute the TruSeq adaptors using the Phusion High
Fidelity DNA Polymerase (New England Biolabs): (98◦C,
15 s; 61◦C, 25 s; 72◦C, 18 s) × 9 cycles. Equal amounts of
the products were pooled and gel purified. The purified li-
brary was deep sequenced using a paired-end 150 bp Illu-
mina MiSeq run. For off-target analysis, we choose 13 po-
tential DNMT1S3 off target sites which were identified and
described previously (12,16). We used the same approach to
build and sequence the Illumina deep sequencing library as
for Cas12a target sites described above.
MiSeq data analysis for editing at target sites or
off-target sites was performed using a suite of Unix-
based software tools. First, the quality of paired-end se-
quencing reads (R1 and R2 fastq files) was assessed
using FastQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). Raw paired-end reads were combined
using paired end read merger (PEAR) (33) to generate
single merged high-quality full-length reads. Reads were
then filtered by quality (using Filter FASTQC (34)) to re-
move those with a mean PHRED quality score under 30
and a minimum per base score under 24. Each group of
reads was then aligned to a corresponding reference se-
quence using BWA (version 0.7.5) and SAMtools (ver-
sion 0.1.19). To determine indel frequency, size and distri-
bution, all edited reads from each experimental replicate
were combined and aligned, as described above. Indel types
and frequencies were then cataloged in a text output for-
mat at each base using bam-readcount (https://github.com/
genome/bam-readcount). For each treatment group, the av-
erage background indel frequencies (based on indel type,
position and frequency) of the triplicate negative control
group were subtracted to obtain the nuclease-dependent in-
del frequencies.
Comparison of the activity of our LbCas12a-2xNLS and
NEB LbCas12a protein
LbCas12a protein was purchased from NEB (EnGen Lba
Cas12a, Catalog # 0653S). For activity comparison in
mammalian cells a DRf–crRNA targeting the AAVS1 lo-
cus (Supplementary Table S8) was in vitro transcribed as de-
scribed above. Different amounts (5pmol, 10pmol, 20pmol,
40pmol and 80pmol) of our LbCas12a or NEB LbCas12a
Protein was mixed with the desired amount crRNAs at 2.5-
fold excess to form each RNP complex. After 15–20 min in-
cubation at room temperature, theRNP complexwasmixed
with 1 × 105 cells in Neon R buffer and electroporated us-
ingNeon®Transfection System (ThermoFisher Scientific)
using the suggested electroporation parameters: Pulse volt-
age (1500v), Pulse width (20ms), Pulse number (2). To com-
pare the activity of our LbCas12a with NEB commercial
LbCas12a protein in zebrafish embryos, we prepared RNP
complex using different amount of our LbCas12a or NEB
LbCas12a protein (4, 8, 16 and 24 fmol) complexed with
the Albino crRNA at 2.5-fold excess, performedmicroinjec-
tion of Cas12a protein and crRNAs into one-cell-stage ze-
brafish embryos as previous described. LbCas12a induced
indel rates in mammalian cells or zebrafish were determined
by deep sequencing as described above.
RESULTS
Improved nuclear localization increases Cas12a activity in
mammalian cells
NLS sequences control the nuclear import of proteins (35).
Previous studies with SpCas9 have reported inefficient nu-
clear localization mediated by a single SV40 NLS (36).
While AsCas12a and LbCas12a have been employed for
effective genome editing in a variety of mammalian sys-
tems, in many prior studies these proteins were modified
to contain only a single NLS appended to the C-terminus
(Cas12a-1C NLS, Figure 1B) (1,9,12,16). However, in the
case of AsCas12a we find that a single NLS leads to inef-
ficient nuclear localization in HEK293T cells (Supplemen-
tary Figure S1). To improve the efficiency of nuclear local-
ization, we examined a number of different combinations of
N- and C-terminal NLSs, and found that the fusion of two
different ofNLSs (SV40 andNucleoplasmin longNLS (35))
onto the C-terminus facilitated the most efficient nuclear
localization of Cas12a (Supplementary Figure S1). Next,
we examined the influence of the different NLS combina-
tions on AsCas12a, LbCas12a and FnoCas12a nuclease ac-
tivity at two previously defined active target sites in human
cells (DNMT1S3 and EMX1S1; Figure 1C, D and Supple-
mentary Table S1) (1). At both genomic target sites, we ob-
served significantly improved lesion frequency associated
with Cas12a proteins bearing two C-terminal NLSs (Fig-
ure 1C and D). Together, these results suggest that improv-
ing the nuclear localization of Cas12a proteins can signifi-
cantly increase lesion frequencies at their respective target
sites.
Consistent with previous studies of the mutational end
products produced by AsCas12a and LbCas12a editing
(1,12), we found that FnoCas12a primarily produced dele-
tions at the DNMT1S3 and EMX1S1 target sites (Supple-
mentary Figures S2A–D and 3A–D). We observed that the
types of deletion products produced for the three differ-
ent Cas12a orthologs were generally similar, although the
rank order of their frequency varied (Supplementary Fig-
ures S2A–L and S3A–L). Consistent with previous obser-
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vations (12), the profile of Cas12a lesions, which are primar-
ily deletions, were distinct from those induced by SpCas9,
which produced smaller deletions and more insertions than
Cas12a (Supplementary Figures S2M–P and S3M-P). No-
tably, many deletions mediated by all three Cas12as have
evidence of short microhomologies flanking the deleted se-
quence segments (e.g. 15 base deletion for FnoCas12a in
Supplementary Figure S2D), as previously reported (12).
Optimization of Cas12a crRNA direct repeat length
The majority of Cas12a studies in mammalian cells have
utilized mature (processed) crRNAs to target the nucle-
ase to a particular locus (1,12,16,19). However, in the na-
tive CRISPR system, the pre-crRNA array is processed by
Cas12a through cleavage within the direct repeat (DR) at
four nucleotides (AAUU; the repeat recognition sequence,
[RRS]) upstream of the stem–loop to generate the ma-
ture crRNA species (DRt-crRNA, Figure 2A) (8). We
examined the impact of including sequence components
from the unprocessed pre-crRNA on the nuclease activ-
ity of Cas12a in mammalian cells. We designed four dif-
ferent crRNAs with different compositions of the Direct
Repeats flanking the core crRNA: truncated Direct-Repeat
crRNA (DRt-crRNA), full-length Direct-Repeat crRNA
(DRf-crRNA), full-length Direct-Repeat crRNA with a
3′ truncated Direct-Repeat (DRf-crRNA-DRt), and full-
length Direct-Repeat crRNA with a 3′ full-length Direct-
Repeat (DRf-crRNA-DRf) (Figure 2A). We tested these
four different crRNA compositions with LbCas12a and
FnoCas12a using the native DR sequence for each nucle-
ase at eleven endogenous target sites in the human genome.
Expression vectors for Cas12a and the crRNA were intro-
duced via transient transfection assays in HEK293T cells.
We found that theDRf-crRNA structure provided the high-
est editing rates for both LbCas12a and FnoCas12a across
11 genomic target sites, whereas crRNA constructs encod-
ing 3′ terminal DR components displayed lower activity
than the mature DRt-crRNA (Figure 2B and C). Consis-
tent with prior studies (1,12), we found that LbCas12a has
higher activity than FnoCas12a at overlapping target se-
quences, but notably FnoCas12a displayed good editing ef-
ficiency when employing the DRf-crRNA framework (me-
dian rate 26.3% versus 34.2% for LbCas12a; Figure 2C).
To examine the requirement for crRNA processing by
Cas12a for the improved activity of the DRf-crRNA con-
structs, we tested the impact on nuclease activity of ei-
ther RNase-dead Cas12a or mutations within the RRS of
the crRNA that reduce processing (8). Lesion rates were
significantly reduced with RNase-dead LbCas12a or Fno-
Cas12a when used in conjunction with DRf-crRNAs (Fig-
ure 2D–G). Likewise, DRf-crRNAs bearing RRS muta-
tions showed decreased lesion rates when used with wild
type Cas12a proteins. By contrast, loss of RNA process-
ing onlymodestly reduced lesion rates associated withDRt-
crRNA (Figure 2D–G). These data demonstrate that the in-
corporation of the full lengthDRat the 5′ end of the Cas12a
crRNA can significantly improve its nuclease activity when
expressed via a U6 promoter, and that this enhanced activ-
ity is dependent on the potential of Cas12a to process the
DR with its RNase cleavage domain.
Optimization of Cas12a crRNA hairpin sequence
There are three A:U base pairs within the stem-loop re-
gion of the DR (37–41). Mutations within the hairpin stem
that disrupt basepairing abolish Cas12a nuclease activity
in vitro, whereas mutations within the stem that preserve
base pairing (e.g. A:U to G:C) do not (1). However the im-
pact of the A:U to G:C substitutions (G–C swap) on edit-
ing in mammalian cells has not been investigated. We hy-
pothesized that increasing the thermal stability of the stem
would potentially increase the fraction of properly folded
crRNA for loading into Cas12a and thereby nuclease activ-
ity. To test this hypothesis, we designed seven different G-C
swapped stem-loop sequences in theDRf-crRNAbackbone
(Figure 3A) and tested their activities on six different en-
dogenous sites in HEK293T cells. We found that simultane-
ous G-C swaps at positions 1 and 3 (DRf-GC@13-crRNA)
showed significantly increased editing efficiencies for both
LbCas12a and FnoCas12a compared with mature crRNAs
(DRt-crRNA) or unmodified full-length Direct Repeat cr-
RNAs (DRf-crRNA) (Figure 3B and C, Supplementary
Figures S4 and S5). We observed similarly increased editing
rates at three sites in HeLa cells using crRNAs with these
modifications (Supplementary Figure S6A and B). These
results illustrate that these improvements in activity are not
a cell-type specific effect. We also evaluated the nuclease
activity of LbCas12a and FnoCas12a protein complexed
with different crRNA frameworks at two target sites when
delivered as ribonucleoprotein complexes (Cas12a RNPs)
by electroporation into HEK293T cells, Jurkat cells and
K562 cells. LbCas12a or FnoCas12a loaded with either
DRf–crRNA orDRf-GC@13-crRNA showed significantly
higher activities than DRt–crRNA (Supplementary Figure
S6C and D). These results demonstrate that across differ-
ent delivery methods and different cell types, these crRNA
modifications can dramatically improve the Cas12a nucle-
ase activity.
To compare the specificity of LbCas12a programmed
with different crRNA frameworks, we carried out targeted
deep sequencing analyses to detect the indels for 13 po-
tential off-target sites for the DNMT1S3 crRNA, which
has been previously characterized by genome-wide deep se-
quencing approaches (12,16). These data indicate that ei-
ther crRNA fused full-length direct repeat (DRf-cr) or si-
multaneous G–C swaps at positions 1 and 3 (DRf-GC@13-
crRNA) did not show significantly higher activities than
DRt–crRNA on these off-target sites (Supplementary Fig-
ure S7, Supplementary Table S4). Thus, these crRNAmodi-
fications do not substantially alter the specificity of Cas12a.
Genome editing in zebrafish embryos
Only a single previous study has successfully utilized Lb-
Cas12a and AsCas12a in zebrafish embryos for targeted
genome editing (22). This work demonstrated activity at
four independent loci, but found that editingwas only possi-
ble when using RNPs rather than mRNA encoded protein.
Furthermore, optimal editing was achieved using a tran-
sient heat shock of embryos at 34◦C (4 h) following Cas12a
RNP injection (22). Therefore, we sought to determine if
the crRNA improvements described above were applicable
in this model system.
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Figure 2. Employing a full-length Direct-Repeat crRNA (DRf-crRNA) enhances editing efficiency. (A) General schematic of four different crRNAs: 19nt-
truncated Direct-Repeat crRNA (DRt-crRNA), 35nt-full-length Direct-Repeat crRNA (DRf-crRNA), full-length Direct-Repeat crRNAwith 3′ truncated
Direct-Repeat (DRf-crRNA-DRt), full-length Direct-Repeat crRNA with 3′ full-length Direct-Repeat (DRf-crRNA-DRf). The 19-nt and 35-nt Direct
Repeats are denoted with the dotted box, the guide sequences are marked in red. Scissors represents the Cas12a RNase domain, which process the crRNA
at the RRS. The nuclease activities of each crRNA type are determined by deep sequencing for LbCas12a (B) and FnoCas12a (C) at 11 endogenous target
sites on genome. Each box represents the 25th and 75th percentile and median is indicated by a line. Whiskers in the box plots are defined by the Tukey
method. Statistical significance is determined by one-way analysis of variance (ANOVA), ‘****’ denotes P < 0.0001 (Supplementary Table S7). Deep
sequencing data are from three independent biological replicates performed on different days with expression constructs delivered by transient transfection
in HEK293T cells (Supplementary Table S2). Error bars indicate ± s.e.m. (D–G). The ability of Cas12a to process the Full-length Direct Repeat (DRf) is
important for enhanced nuclease activity of this crRNA. Evaluation of the editing activity ofWild-type (WT) or RNase-dead Cas12a with different crRNA
constructs (wild-type crRNA sequence or crRNA containing a mutation within the RRS sequence of crRNA) for LbCas12a (D, E) and FnoCas12a (F,
G) at the DNMT1S3 (D, F) and EMX1S1 (E, G) target sites. Lesion rates determined by deep sequencing. Data are from three independent biological
replicates performed on different days with expression constructs delivered by transient transfection in HEK293T cells (Supplementary Table S2). Error
bars indicate ±s.e.m. Statistical significance is determined by two-tailed Student’s t-test: ‘***’ denote P < 0.001, ‘**’ denote P < 0.01, ‘*’ denote P < 0.05,
respectively (Supplementary Table S7).
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Figure 3. G-C swaps at specific position in the stem of the direct repeat increase editing efficiency. (A) General schematic of G–C swaps (indicated in red) at
different position in the stem of the direct repeat hairpin. The activities of 9 different G-C swap crRNAs are determined by deep sequencing for LbCas12a
(B) and FnoCas12a (C) at six different endogenous target sites on genome. Each box represents the 25th and 75th percentile and the middle line is the
median. Whiskers in the box plots are defined by the Tukey method. Deep sequencing data are from three independent biological replicates performed
on different days with expression constructs delivered by transient transfection in HEK293T cells (Supplementary Table S3). Error bars indicate ± s.e.m.
Statistical significance is determined by one-way analysis of variance (ANOVA), ‘**’ and ‘***’ denote P < 0.01 and <0.001 respectively (Supplementary
Table S7).
Since our Cas12a proteins differ in the composition of
the C-terminal NLSs from those that were previously de-
scribed (22), we performed an initial set of injections using
4 fmol LbCas12a RNP targeting four different sites at two
genomic loci. In these injections, we evaluated three differ-
ent crRNA frameworks (DRt-crRNA, DRf-crRNA, and
DRf-GC@13-crRNA), which were synthesized by in vitro
transcription. Following RNP injections, we performed
deep sequencing on PCR amplicons spanning genomic tar-
get sites from treated embryos at 24 h post fertilization
(hpf) to determine lesion rates. The DRf-crRNA signif-
icantly increased editing rates in embryos maintained at
28.5◦C compared to DRt-crRNA (Figure 4A and B) and
this effect was further enhanced with heat shock at 34◦C
(Figure 4A and C). At all four target sites, we also ob-
served significant increases in lesion rates with RNPs con-
taining the DRf-GC@13-crRNA in comparison to DRf-
crRNA (Figure 4A–C). Importantly, there were no signif-
icant increases in toxicity associated with the higher edit-
ing rates achieved with either the DRf-crRNA or DRf-
GC@13-crRNA frameworks (Supplementary Figure S8A
and B). For one of the least active target sites (gata2a cr2),
we performed a dose response analysis spanning four Lb-
Cas12a:crRNA concentrations (4, 8, 16 and 24 fmol), which
revealed increasing mutagenesis as a function of nuclease
concentration (Supplementary Figure S9A). At the highest
dose (24 fmol), lesion rates approached 100% for the heat
shocked embryos for all crRNA configurations (Supple-
mentary Figure S9B and C) without substantial increases
in toxicity with higher LbCas12a RNP dose (Supplemen-
tary Figure S9D).
Based on the LbCas12a:crRNA titration data, we exam-
ined the ability of 24 fmol LbCas12a RNPs programmed
with the three different crRNA frameworks to edit ten
target sites spanning four different genomic loci including
some intronic sequences, which are easier to target with
Cas12a than SpCas9 (22). Deep sequencing analysis of
locus-specific editing rates revealed that both DRf–crRNA
and DRf-GC@13-crRNA produced modestly higher mu-
tagenesis levels than DRt–crRNA at these ten different tar-
get sites with or without heat shock (Figure 4). Consistent
with the Moreno-Mateos study (22), we also observed that
heat shock of the embryos at 34◦C post injection modestly
increased LbCas12a-mediated gene editing in aggregate at
the ten target sites for each crRNA composition (Supple-
mentary Figure S10A). Notably, lesion rates using these op-
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Figure 4. Genome Editing by LbCas12a in zebrafish embryos. (A) Activity profiles of truncated Direct-Repeat crRNA (DRt-crRNA), full-length Direct-
Repeat crRNA (DRf-crRNA) and G–C swapped crRNA (DRf-GC@13-crRNA) at four genomic sites in zebrafish embryos with and without heat shock
using 4fmol RNP. Lesion rates are determined by deep sequencing. An aggregate analysis of the editing data (four target sites times three replicates) shows
a significant increase in genome editing efficiency in fish embryos without heatshock (B) or with heatshock (C) for the DRf-crRNA and the DRf-GC@13-
crRNA relative to the DRt-crRNA. (D) Activity profiles of three different crRNA frameworks at ten genomic sites in zebrafish embryos with and without
heat shock treated with 24 fmol LbCas12a RNP. In the aggregate analysis across all ten target sites the DRf-GC@13-crRNA also provides a significant
increase in genome editing efficiency in fish embryos without heatshock (E) or with heatshock (F). Deep sequencing data are from zebrafish embryos from
three independent injections by three different individuals (Supplementary Table S5). For the bar charts, error bars indicate ± s.e.m. For each dot plot the
three lines represent 75th, 50th and 25th percentile, respectively. Statistical significance is determined by one-way analysis of variance (ANOVA), ‘*’, ‘**’,
‘****’ denotes P values of <0.05, <0.01 and <0.0001, respectively (Supplementary Table S7).
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timized conditions exceeded 75% across all ten target sites.
Accordingly, embryos injected with LbCas12a:crRNA tar-
geting albino displayed a complete loss of pigmentation con-
sistent with inactivation of both alleles (Supplementary Fig-
ure S10B). Analysis of the indels produced at these tar-
get sites revealed that the mutagenic end-products in the
zebrafish embryos are microhomology-driven, similar to
the observations inmammalian cell culture (Supplementary
Figures S11–S16) (12). Interestingly, the spectrum of dele-
tions that are produced within the embryos changed in the
heat shock treated cohort, with a trend toward the reduction
of insertions and creation of larger deletions in the genomes
of heat shocked animals (Supplementary Figures S11–S16
and S21).
Given our promising results with FnoCas12a editing in
mammalian cells, we examined its efficacy in zebrafish em-
bryos. Because FnoCas12a recognizes a TTNPAM element
(1,25,26), it should be able to target a wider spectrum of se-
quences within the genome than LbCas12a (TTTV PAM).
Based on the results with LbCas12a, we employed the most
active crRNA configuration (DRf-GC@13-crRNA) at a 24
fmol RNP dose to evaluate FnoCas12a activity at the same
ten target sites. Lesions were observed at all ten sites with
a median rate of >50%, with heat shock modestly increas-
ing the indel rates and shifting the distribution of products
toward deletions (Supplementary Figures S17–21). At five
of the ten target loci FnoCas12a was just as effective as Lb-
Cas12a in producing targeted mutagenesis, suggesting that
FnoCas12a can provide an important alternative nuclease
for zebrafish mutagenesis when an appropriate PAM is not
available for SpCas9 or LbCas12a. Collectively, these re-
sults demonstrate that delivery of pre-assembled Cas12a-
crRNA RNP complexes provides a robust genome editing
system in zebrafish.
DISCUSSION
Type V CRISPR–Cas12a systems are a more recent addi-
tion to the genome editing toolbox (1,3) that are still be-
ing optimized for editing in vertebrate systems. Herein we
describe improvements to the Cas12a nuclease components
that improve editing rates in mammalian cells and zebrafish
embryos. Suzuki and colleagues compared the editing ac-
tivities, and nuclear localization of SpCas9 fused to differ-
ent types of NLSs, which revealed that a bipartite NLS was
superior to the standard SV40 NLS (36). Similar to these
results for SpCas9, we find that the degree of nuclear lo-
calization and editing rates for three different Cas12as are
improved by two C-terminus NLSs, one of which (Nucleo-
plasmin NLS) is bipartite in nature (42). It is possible that
both the number and the composition of the NLSs impact
nuclease activity, as a comparison of the editing efficiency of
our LbCas12a with that of NEB LbCas12a, which contains
two SV40 NLSs, revealed improved activity in mammalian
cells (AAVS1) and zebrafish embryos (slc45a2; Supplemen-
tary Figure S22).
We also examined the impact of different crRNA com-
positions on the editing rate of Cas12a. We found that the
inclusion of the full-lengthDirect Repeat improved the edit-
ing rates for Cas12a in mammalian cells and zebrafish em-
bryos. This enhancement of activity was irrespective of the
delivered form of the nuclease (transient plasmid transfec-
tion or Cas12a-crRNA RNP using in vitro transcribed cr-
RNAs). Moreno-Mateos and colleagues also examined the
use of the full-length Direct Repeat crRNA (DRf-crRNA)
to program LbCas12a and AsCas12a for editing in ze-
brafish embryos (22). While there was little comparative
analysis between the DRt-crRNA and the DRf-crRNA in
that study, their data suggested that Cas12a programmed
with the full-length DR may have increased activity in
zebrafish embryos, which is consistent with our analysis.
While our study was being completed, a similar conclusion
about the enhancement in activity for extended crRNAs in
mammalian cells was reached in another study (43). Unique
to our analysis, we demonstrate that crRNA processing by
Cas12a is an important component for the enhancement
in editing rates achieved with the full length DR, as mu-
tation of the RRS or mutation of the RNase domain within
Cas12a dramatically reduced the activity of Cas12a loaded
with a full length DR crRNA.
Prior studies have examined the impact of chemical mod-
ifications within the crRNA or changes to the native cr-
RNA sequence on Cas12a editing rates in vitro and in mam-
malian cells (1,8,43–45). We incorporated isosteric A:U to
G:C base substitutions within the hairpin stem in an at-
tempt to increase the thermal stability of the pseudoknot
that forms the core RNA structure recognized by Cas12a
(37–41). Interestingly, Cas12a makes few, if any, base spe-
cific contacts with the core of the hairpin stem of the pseu-
doknot (38,39) suggesting that it may be tolerant to more
radical changes within this region that preserve the struc-
ture but alter its stability. However, sequence changes that
extend or reduce the length of the hairpin stem (8,44), or
create mismatches within the stem (1) have been shown to
disrupt Cas12a activity. Note that our base substitutions
were utilized in the context of the full-length direct repeat
crRNAs produced by transcription. Their inclusion in the
context of truncated synthetic crRNAs may not be benefi-
cial.
Importantly, improvements in Cas12a activity associated
with these crRNA modifications in mammalian cells trans-
lated to zebrafish embryos. Interestingly, the improvements
in activity for the modified crRNAs were only apparent
at the lower concentration injections for Cas12a (4 and 8
fmol RNP, Supplementary Figure S9). At higher concen-
trations (24 fmoles), we observed saturation of the editing
rates, such that even heat shock only had a minor impact
on the bulk edit rates in the injected population for the tar-
get sequences (Figure 4C and D). The 24 fmol dose is sub-
stantially higher than the highest LbCas12a injection dose
(10 fmol) employed by Moreno-Mateos et al. (22), and yet
that we find this dose is still well tolerated by the zebrafish,
with >70% developing normally and no statistically sig-
nificant increase in mortality (Supplementary Figure S8).
Finally, we find that the utilization of heat shock on the
embryos shifts the distribution of indels towards deletions
with larger segments being removed (Supplementary Figure
S21). Thus, the utilization of heatshock with Cas12a editing
in zebrafish embryos can not only increase editing rates, but
may also increase the production of sequence modifications
that are more likely to be disruptive to gene function (dele-
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tion of critical elements for protein function or nearby splice
sites).
The demonstration that FnoCas12a, which utilizes a
TTN PAM, has robust activity should also provide util-
ity for zebrafish genome editing given its broader target-
ing range than LbCas12a. Although the FnoCas12a sys-
tem had overall lower editing rates than LbCas12a in both
mammalian cells and zebrafish embryos in our experiments,
for 50% of the target sites in zebrafish it achieved similar
editing efficiency to LbCas12a. Given that FnoCas12a can
potentially target more than four times as many sequences
within the zebrafish genome, this nuclease could be partic-
ularly useful for the targeted knock in of DNA sequences,
since the efficiency of knock-in is a function of the proximity
of the nuclease target site to the desired sequence alteration
(46).
The extremely high editing rates and the low toxicity that
is observed for LbCas12a suggests that this system may
be amenable to F0 reverse genetic screens in zebrafish. F0
screens in zebrafish have been employed successfully with
SpCas9 RNP injections (47,48). However, the efficiency of
LbCas12a editing, its low toxicity and the prevalence for
this nuclease to create deletions within the target sequence
may provide an interesting alternative to SpCas9. In ad-
dition, since LbCas12a has more target sites within the
zebrafish coding sequence than SpCas9 (22), it or other
Cas12a variants that are being characterized (1,25) may
maximize the rate of inactivation of a single locus in the
context of multiplexed guides (48). We anticipate that the
modifications to the Cas12a system described herein that
increase editing rates for both plasmid expression systems
and RNPs should have broad utility for editing in a variety
of eukaryotic systems.
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